In the complex landscape of ocular health, one condition can often serve as a gateway to discovering another. New research from China suggests that patients diagnosed with retinal vein occlusion (RVO) may be carrying an undetected burden of glaucoma, a finding that could fundamentally change how clinicians approach the screening of retinal vascular diseases.
The study underscores a critical gap in current diagnostic patterns: glaucoma often goes unsuspected in vein occlusion cases, remaining hidden until a secondary vascular event brings the patient into a clinic. Because both conditions can lead to irreversible vision loss, the intersection of these two diseases creates a high-risk scenario for permanent blindness if not managed proactively.
Between 2018 and 2025, researchers tracked 610 subjects with RVO to determine the prevalence of primary glaucoma. The results revealed that 15.4% of these patients—a total of 94 individuals—were diagnosed with primary glaucoma. More concerningly, nearly half of those cases had gone unnoticed until the RVO presented itself.
As a physician and medical writer, I have seen how “silent” diseases can migrate through a patient’s system, often only surfacing when a more acute symptom appears. In this case, the RVO acts as the catalyst for a diagnosis that might have otherwise remained invisible until the patient experienced significant, irreversible sight loss.
| Subtypes of glaucoma at varying severities can develop in patients with retinal vein occlusion, including primary open-angle glaucoma, normal-tension glaucoma, primary angle-closure glaucoma and chronic angle-closure glaucoma.Photo: Optos. Click image to enlarge. |
The Hidden Prevalence of Primary Glaucoma
The study’s data reveals a nuanced distribution of glaucoma subtypes among those suffering from retinal vascular disease. While the general association between RVO and primary open-angle glaucoma has been documented in previous literature, this research provides more specific prevalence rates that highlight the breadth of the problem.
Of the 94 patients diagnosed with primary glaucoma, 56 (9.2% of the total RVO cohort) had primary open-angle glaucoma, while 38 (6.2%) were diagnosed with primary angle-closure glaucoma. This suggests that the risk is not limited to a single form of the disease but spans multiple manifestations of increased intraocular pressure and optic nerve damage.
The most striking statistic from the researchers is that 45.7% of primary glaucoma cases were underdiagnosed at the time of RVO presentation. This implies that nearly one in two patients with both conditions were unaware of their glaucoma, potentially missing years of critical treatment that could have preserved their visual field.
Understanding the Impact on Vision
To understand why this overlap is so dangerous, one must look at how these two conditions disrupt the eye. Glaucoma typically involves damage to the optic nerve, often caused by abnormally high pressure inside the eye, leading to a gradual loss of peripheral vision. Retinal vein occlusion, conversely, occurs when a vein in the retina becomes blocked, causing fluid to leak into the retina and potentially leading to sudden vision loss or macular edema.
When these conditions coexist, the eye is attacked from two different angles: one through the vascular system and the other through the drainage and pressure systems. This dual pathology accelerates the risk of irreversible blindness, making early detection a matter of urgency.
Why Systemic Screening is Now Essential
The authors of the study argue that the current approach to RVO is insufficient if it does not include a comprehensive glaucoma workup. Because the symptoms of early-stage glaucoma are often subtle—essentially invisible to the patient until significant damage has occurred—the “systemic glaucoma screening” they propose is designed to catch the disease in its asymptomatic phase.
The researchers noted that while the association between the two is clear, the specific prevalence rates have remained limited in previous studies. By implementing a rigorous screening protocol for every patient presenting with RVO, clinicians can identify the “hidden” glaucoma cases that would otherwise go unnoticed.
| Glaucoma Subtype | Patient Count | Percentage of Total Cohort |
|---|---|---|
| Primary Open-Angle Glaucoma | 56 | 9.2% |
| Primary Angle-Closure Glaucoma | 38 | 6.2% |
| Total Primary Glaucoma | 94 | 15.4% |
Clinical Constraints and Future Implications
Despite the clear findings, the researchers urged caution in interpreting the data, noting that the observational design of the study limits the ability to establish a direct causal link. However, the correlation is strong enough to warrant a shift in clinical practice. The goal is to move from a reactive model—treating the vein occlusion as it appears—to a proactive model that screens for the underlying pressure issues that define glaucoma.
For patients, this means that a diagnosis of a retinal vascular disease should be viewed as a “red flag” for other ocular health issues. It highlights the necessity of comprehensive eye exams that go beyond the retina to include tonometry (pressure testing) and optic nerve evaluation.
The long-term impact of this discovery lies in the prevention of blindness. Because glaucoma is manageable if caught early, the identification of these “hidden” cases during an RVO presentation could save the sight of thousands of patients who would otherwise remain undiagnosed.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
As medical professionals continue to analyze the relationship between vascular health and intraocular pressure, the next step will likely involve larger, longitudinal studies to determine if RVO is a precursor to glaucoma or if a shared systemic risk factor—such as hypertension or diabetes—drives both conditions. Updated clinical guidelines for retinal vascular disease management are expected to evolve as more observational data becomes available.
If you or a loved one have experienced vision changes, we encourage you to share your experience in the comments or share this article with others who may benefit from increased screening awareness.
